Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo de Witte

Showing results (81-90 of 151) with videos related to

Pageof 16
Sort By:
Nature Genetics|July 6, 2010
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromesGorica Nikoloski, Saskia M C Langemeijer, Roland P Kuiper, et al.
British Journal of Haematology|September 13, 2021
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMTAvichai Shimoni, Marie Robin, Simona Iacobelli, et al.
Plos One|October 12, 2013
Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized dataRonald Brand, Hein Putter, Anja van Biezen, et al.
Haematologica|August 3, 2014
Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working PartyFrancesco Onida, Ronald Brand, Anja van Biezen, et al.
Blood|March 17, 2024
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G CommitteeFrancesco Onida, Nico Gagelmann, Yves Chalandon, et al.
Annals of Hematology|March 31, 2012
Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative GroupsMarysia Hengeveld, Stefan Suciu, Matthias Karrasch, et al.
Blood Advances|September 7, 2021
Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologistsIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
British Journal of Haematology|July 28, 2015
Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow TransplantationArgiris Symeonidis, Anja van Biezen, Liesbeth de Wreede, et al.
Blood|March 12, 2005
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studySergio Amadori, Stefan Suciu, Ulrich Jehn, et al.
Cancers|November 14, 2020
Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON TrialsSafaa M Ramadan, Stefan Suciu, Marian J P L Stevens-Kroef, et al.
Pageof 16

Showing results (81-90 of 151) with videos related to

Sort By:
Pageof 16
Nature Genetics|July 6, 2010
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromesGorica Nikoloski, Saskia M C Langemeijer, Roland P Kuiper, et al.
British Journal of Haematology|September 13, 2021
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMTAvichai Shimoni, Marie Robin, Simona Iacobelli, et al.
Plos One|October 12, 2013
Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized dataRonald Brand, Hein Putter, Anja van Biezen, et al.
Haematologica|August 3, 2014
Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working PartyFrancesco Onida, Ronald Brand, Anja van Biezen, et al.
Blood|March 17, 2024
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G CommitteeFrancesco Onida, Nico Gagelmann, Yves Chalandon, et al.
Annals of Hematology|March 31, 2012
Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative GroupsMarysia Hengeveld, Stefan Suciu, Matthias Karrasch, et al.
Blood Advances|September 7, 2021
Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologistsIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
British Journal of Haematology|July 28, 2015
Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow TransplantationArgiris Symeonidis, Anja van Biezen, Liesbeth de Wreede, et al.
Blood|March 12, 2005
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studySergio Amadori, Stefan Suciu, Ulrich Jehn, et al.
Cancers|November 14, 2020
Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON TrialsSafaa M Ramadan, Stefan Suciu, Marian J P L Stevens-Kroef, et al.
Pageof 16